Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies

PHASE3CompletedINTERVENTIONAL
Enrollment

918

Participants

Timeline

Start Date

September 3, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

10d bismuth quadruple therapy

rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days

DRUG

14d hybrid therapy

a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days

DRUG

14D high-dose dual therapy

rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days

Trial Locations (1)

813

Kaohsiung Veterans General Hospital, Kaohsiung City

All Listed Sponsors
lead

Kaohsiung Veterans General Hospital.

OTHER

NCT03779074 - Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies | Biotech Hunter | Biotech Hunter